Clinical Kidney Journal, sfx151, https://doi.org/10.1093/ckj/sfx151 The online version has been updated to correct an error in Table 1. Table 1. Patient characteristics of all patients and the propensity score-matched cohort All (n = 1282) Propensity score 2:1 matched (n = 735) ESWL URS P-value ESWL URS P-value Number of patients (%) 999 (78) 283 (22) 490 (67) 245 (33) Age, years (±SD) 49 (15.0) 51 (14.4) 0.124 50 (15.0) 51 (14.2) 0.685 Female (%) 274 (27.4) 74 (26.1) 0.669 126 (25.7) 71 (29.0) 0.346 Male (%) 725 (72.6) 209 (73.9) 364 (74.3) 174 (71.0) BMI, kg/m2 (±SD) 27 (4.75) 27 (4.64) 0.596 27 (4.4) 27 (4.9) 0.790 Size of biggest stone, mm (IQR) 9 (7–11) 8 (6–11) <0.001 8 (6–10) 8 (6–12) 0.988 Number of stones (%) <0.001 0.722 1 49 51 57 58 2 15 25 26 22 3 7 13 11 11 >3 4 11 5 9 Complications (%) Clavien II 24 (2.4) 20 (7.1) <0.001 17 (3.5) 17 (6.9) <0.001 Clavien IIIa 8 (0.8) 0 (0) 0.21 3 (0.6) 0 (0) Clavien IIIb 5 (0.5) 1 (0.4) 0.30 3 (0.6) 1 (0.4) Clavien IV 0 0 0 (0) 0 (0) All (n = 1282) Propensity score 2:1 matched (n = 735) ESWL URS P-value ESWL URS P-value Number of patients (%) 999 (78) 283 (22) 490 (67) 245 (33) Age, years (±SD) 49 (15.0) 51 (14.4) 0.124 50 (15.0) 51 (14.2) 0.685 Female (%) 274 (27.4) 74 (26.1) 0.669 126 (25.7) 71 (29.0) 0.346 Male (%) 725 (72.6) 209 (73.9) 364 (74.3) 174 (71.0) BMI, kg/m2 (±SD) 27 (4.75) 27 (4.64) 0.596 27 (4.4) 27 (4.9) 0.790 Size of biggest stone, mm (IQR) 9 (7–11) 8 (6–11) <0.001 8 (6–10) 8 (6–12) 0.988 Number of stones (%) <0.001 0.722 1 49 51 57 58 2 15 25 26 22 3 7 13 11 11 >3 4 11 5 9 Complications (%) Clavien II 24 (2.4) 20 (7.1) <0.001 17 (3.5) 17 (6.9) <0.001 Clavien IIIa 8 (0.8) 0 (0) 0.21 3 (0.6) 0 (0) Clavien IIIb 5 (0.5) 1 (0.4) 0.30 3 (0.6) 1 (0.4) Clavien IV 0 0 0 (0) 0 (0) Bold P-values indicate statistical significance. Table 1. Patient characteristics of all patients and the propensity score-matched cohort All (n = 1282) Propensity score 2:1 matched (n = 735) ESWL URS P-value ESWL URS P-value Number of patients (%) 999 (78) 283 (22) 490 (67) 245 (33) Age, years (±SD) 49 (15.0) 51 (14.4) 0.124 50 (15.0) 51 (14.2) 0.685 Female (%) 274 (27.4) 74 (26.1) 0.669 126 (25.7) 71 (29.0) 0.346 Male (%) 725 (72.6) 209 (73.9) 364 (74.3) 174 (71.0) BMI, kg/m2 (±SD) 27 (4.75) 27 (4.64) 0.596 27 (4.4) 27 (4.9) 0.790 Size of biggest stone, mm (IQR) 9 (7–11) 8 (6–11) <0.001 8 (6–10) 8 (6–12) 0.988 Number of stones (%) <0.001 0.722 1 49 51 57 58 2 15 25 26 22 3 7 13 11 11 >3 4 11 5 9 Complications (%) Clavien II 24 (2.4) 20 (7.1) <0.001 17 (3.5) 17 (6.9) <0.001 Clavien IIIa 8 (0.8) 0 (0) 0.21 3 (0.6) 0 (0) Clavien IIIb 5 (0.5) 1 (0.4) 0.30 3 (0.6) 1 (0.4) Clavien IV 0 0 0 (0) 0 (0) All (n = 1282) Propensity score 2:1 matched (n = 735) ESWL URS P-value ESWL URS P-value Number of patients (%) 999 (78) 283 (22) 490 (67) 245 (33) Age, years (±SD) 49 (15.0) 51 (14.4) 0.124 50 (15.0) 51 (14.2) 0.685 Female (%) 274 (27.4) 74 (26.1) 0.669 126 (25.7) 71 (29.0) 0.346 Male (%) 725 (72.6) 209 (73.9) 364 (74.3) 174 (71.0) BMI, kg/m2 (±SD) 27 (4.75) 27 (4.64) 0.596 27 (4.4) 27 (4.9) 0.790 Size of biggest stone, mm (IQR) 9 (7–11) 8 (6–11) <0.001 8 (6–10) 8 (6–12) 0.988 Number of stones (%) <0.001 0.722 1 49 51 57 58 2 15 25 26 22 3 7 13 11 11 >3 4 11 5 9 Complications (%) Clavien II 24 (2.4) 20 (7.1) <0.001 17 (3.5) 17 (6.9) <0.001 Clavien IIIa 8 (0.8) 0 (0) 0.21 3 (0.6) 0 (0) Clavien IIIb 5 (0.5) 1 (0.4) 0.30 3 (0.6) 1 (0.4) Clavien IV 0 0 0 (0) 0 (0) Bold P-values indicate statistical significance. has been changed to Table 1. Patient characteristics of all patients and the propensity score-matched cohort All (n = 1282) Propensity score 2:1 matched (n = 735) ESWL URS P-value ESWL URS P-value Number of patients (%) 999 (78) 283 (22) 490 (67) 245 (33) Age (±SD) 49.4 (15.0) 50.9 (14.4) 0.124 50.1 (15.0) 50.7 (14.2) 0.685 Female (%) 274 (27.4) 74 (26.1) 0.669 126 (25.7) 71 (29.0) 0.346 Male (%) 725 (72.6) 209 (73.9) 364 (74.3) 174 (71.0) BMI (±SD) 26.74 (4.75) 26.56 (4.64) 0.596 26.6 (4.4) 26.7 (4.9) 0.790 Size of biggest stone, in mm (IQR) 9 (7–11) 8 (6–11) <0.001 8 (6–10) 8 (6–12) 0.988 Number of stones 1 stone 74.8% 50.7% <0.001 57.0% 57.6% 0.722 2 stones 15.1% 25.3% 26.3% 22.2% 3 stones 6.6% 13.3% 11.3% 11.1% >3 stones 3.5% 10.7% 5.4% 9.1% Complications (%) Clavien II 24 (2.4) 20 (7.1) <0.001 17 (3.5) 17 (6.9) <0.001 Clavien IIIa 8 (0.8) 0 (0) 0.21 3 (0.6) 0 (0) Clavien IIIb 5 (0.5) 1 (0.4) 0.30 3 (0.6) 1 (0.4) Clavien IV 0 0 0 (0) 0 (0) All (n = 1282) Propensity score 2:1 matched (n = 735) ESWL URS P-value ESWL URS P-value Number of patients (%) 999 (78) 283 (22) 490 (67) 245 (33) Age (±SD) 49.4 (15.0) 50.9 (14.4) 0.124 50.1 (15.0) 50.7 (14.2) 0.685 Female (%) 274 (27.4) 74 (26.1) 0.669 126 (25.7) 71 (29.0) 0.346 Male (%) 725 (72.6) 209 (73.9) 364 (74.3) 174 (71.0) BMI (±SD) 26.74 (4.75) 26.56 (4.64) 0.596 26.6 (4.4) 26.7 (4.9) 0.790 Size of biggest stone, in mm (IQR) 9 (7–11) 8 (6–11) <0.001 8 (6–10) 8 (6–12) 0.988 Number of stones 1 stone 74.8% 50.7% <0.001 57.0% 57.6% 0.722 2 stones 15.1% 25.3% 26.3% 22.2% 3 stones 6.6% 13.3% 11.3% 11.1% >3 stones 3.5% 10.7% 5.4% 9.1% Complications (%) Clavien II 24 (2.4) 20 (7.1) <0.001 17 (3.5) 17 (6.9) <0.001 Clavien IIIa 8 (0.8) 0 (0) 0.21 3 (0.6) 0 (0) Clavien IIIb 5 (0.5) 1 (0.4) 0.30 3 (0.6) 1 (0.4) Clavien IV 0 0 0 (0) 0 (0) Bold P-values indicate statistical significance. Table 1. Patient characteristics of all patients and the propensity score-matched cohort All (n = 1282) Propensity score 2:1 matched (n = 735) ESWL URS P-value ESWL URS P-value Number of patients (%) 999 (78) 283 (22) 490 (67) 245 (33) Age (±SD) 49.4 (15.0) 50.9 (14.4) 0.124 50.1 (15.0) 50.7 (14.2) 0.685 Female (%) 274 (27.4) 74 (26.1) 0.669 126 (25.7) 71 (29.0) 0.346 Male (%) 725 (72.6) 209 (73.9) 364 (74.3) 174 (71.0) BMI (±SD) 26.74 (4.75) 26.56 (4.64) 0.596 26.6 (4.4) 26.7 (4.9) 0.790 Size of biggest stone, in mm (IQR) 9 (7–11) 8 (6–11) <0.001 8 (6–10) 8 (6–12) 0.988 Number of stones 1 stone 74.8% 50.7% <0.001 57.0% 57.6% 0.722 2 stones 15.1% 25.3% 26.3% 22.2% 3 stones 6.6% 13.3% 11.3% 11.1% >3 stones 3.5% 10.7% 5.4% 9.1% Complications (%) Clavien II 24 (2.4) 20 (7.1) <0.001 17 (3.5) 17 (6.9) <0.001 Clavien IIIa 8 (0.8) 0 (0) 0.21 3 (0.6) 0 (0) Clavien IIIb 5 (0.5) 1 (0.4) 0.30 3 (0.6) 1 (0.4) Clavien IV 0 0 0 (0) 0 (0) All (n = 1282) Propensity score 2:1 matched (n = 735) ESWL URS P-value ESWL URS P-value Number of patients (%) 999 (78) 283 (22) 490 (67) 245 (33) Age (±SD) 49.4 (15.0) 50.9 (14.4) 0.124 50.1 (15.0) 50.7 (14.2) 0.685 Female (%) 274 (27.4) 74 (26.1) 0.669 126 (25.7) 71 (29.0) 0.346 Male (%) 725 (72.6) 209 (73.9) 364 (74.3) 174 (71.0) BMI (±SD) 26.74 (4.75) 26.56 (4.64) 0.596 26.6 (4.4) 26.7 (4.9) 0.790 Size of biggest stone, in mm (IQR) 9 (7–11) 8 (6–11) <0.001 8 (6–10) 8 (6–12) 0.988 Number of stones 1 stone 74.8% 50.7% <0.001 57.0% 57.6% 0.722 2 stones 15.1% 25.3% 26.3% 22.2% 3 stones 6.6% 13.3% 11.3% 11.1% >3 stones 3.5% 10.7% 5.4% 9.1% Complications (%) Clavien II 24 (2.4) 20 (7.1) <0.001 17 (3.5) 17 (6.9) <0.001 Clavien IIIa 8 (0.8) 0 (0) 0.21 3 (0.6) 0 (0) Clavien IIIb 5 (0.5) 1 (0.4) 0.30 3 (0.6) 1 (0.4) Clavien IV 0 0 0 (0) 0 (0) Bold P-values indicate statistical significance. © The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Clinical Kidney Journal – Oxford University Press
Published: Apr 1, 2019
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”
Daniel C.
“Whoa! It’s like Spotify but for academic articles.”
@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”
@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”
@JoseServera
DeepDyve Freelancer | DeepDyve Pro | |
---|---|---|
Price | FREE | $49/month |
Save searches from | ||
Create folders to | ||
Export folders, citations | ||
Read DeepDyve articles | Abstract access only | Unlimited access to over |
20 pages / month | ||
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.